Evaluation of liposomal formulations containing the antimalarial agent, arteether

Al‐Angary, A. A.; Al‐Meshal, M. A.; Bayomi, Mohsen A.; Khidr, S. H.

doi:10.1016/0378-5173(95)04273-3

Cited by 26 publications

(9 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is known that adding cholesterol to the formulations has been shown to decrease the encapsulation of hydrophobic drugs because cholesterol locates on the limited hydrophobic space in the lipid membrane . Similar results have been reported with respect to chain lengths of phospholipids . Incorporation of INH in the aqueous phase was confirmed by other researcher …”

Section: Resultssupporting

confidence: 91%

“…[37] T A B L E 2 Encapsulation (%), loading (%), and release (%) results of INH and RIF in archaeosome and liposome-containing drug alone or Similar results have been reported with respect to chain lengths of phospholipids. [38,39] Incorporation of INH in the aqueous phase was confirmed by other researcher. [15,16] Liposomes and archaeosomes were investigated as sustained release antitubercular drug carriers for INH and RIF.…”

Section: Drug Loading Encapsulation and Release Studiesmentioning

confidence: 58%

See 1 more Smart Citation

Preparation, characterization, and in vitro evaluation of isoniazid and rifampicin‐loaded archaeosomes

et al. 2017

View full text Add to dashboard Cite

The ability of Archaea to adapt their membrane lipid compositions to extreme environments has brought in archaeosomes into consideration for the development of drug delivery systems overcoming the physical, biological blockades that the body exhibits against drug therapies. In this study, we prepared unilamellar archaeosomes, from the polar lipid fraction extracted from Haloarcula 2TK2 strain, and explored its potential as a drug delivery vehicle. Rifampicin and isoniazid which are conventional drugs in tuberculosis medication were loaded separately and together in the same archaeosome formulation for the benefits of the combined therapy. Particle size and zeta potential of archaeosomes were measured by photon correlation spectroscopy, and the morphology was assessed by with an atomic force microscope. Encapsulation efficiency and loading capacities of the drugs were determined, and in vitro drug releases were monitored spectrophotometrically. Our study demonstrates that rifampicin and isoniazid could be successfully loaded separately and together in archaeosomes with reasonable drug-loading and desired vesicle-specific characters.Both of the drugs had greater affinity for archaeosomes than a conventional liposome formulation. The results imply that archaeosomes prepared from extremely halophilic archaeon were compatible with the liposomes for the development of stable and sustained release of antituberculosis drugs.

show abstract

Section: Resultssupporting

confidence: 91%

Section: Drug Loading Encapsulation and Release Studiesmentioning

confidence: 58%

Preparation, characterization, and in vitro evaluation of isoniazid and rifampicin‐loaded archaeosomes

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The high percentage of the polymer can promote better wettability with an improved solubility due to the complete dispersion of the drug in the solid dispersion, resulting in high drug release. Identical findings were demonstrated for lorazepam–PEG solid dispersion, where a linear relation was found for polymer weight ratio and the dissolution rate constant 44…”

Section: Resultsmentioning

confidence: 92%

“…It is clear that morphological differences were seen between the two drugs and their physical mixtures and solid dispersion counterparts. Drug must be dispersed/soluble/reduced in particle size within the solid dispersions without crystal formation in order to enhance the dissolution profile 44. These observations also show that the determinations from the DSC study are tenable.…”

Section: Resultsmentioning

confidence: 99%

Physicochemical characterisation, drug polymer dissolution and in vitro evaluation of phenacetin and phenylbutazone solid dispersions with polyethylene glycol 8000

Khan

Batchelor

Hanson

et al. 2011

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

“…Artemether (AM), an antimalarial drug introduced in 1988 [108], has been encapsulated in neutral multilamellar liposomal formulations to be used by the oral route [109]. Evidence was found that the type of the phospholipid, as well as the incorporation of cholesterol in the liposomal bilayer, altered the AM entrapment efficiency, the size of the liposomes and the drug release rate.…”

Section: Conventional and Long-circulating Neutral Liposomesmentioning

confidence: 99%

Nanotechnology applied to the treatment of malaria

Santos-Magalhães

Mosqueira

2010

Advanced Drug Delivery Reviews

255

158

View full text Add to dashboard Cite

Despite the fact that we live in an era of advanced technology and innovation, infectious diseases, like malaria, continue to be one of the greatest health challenges worldwide. The main drawbacks of conventional malaria chemotherapy are the development of multiple drug resistance and the non-specific targeting to intracellular parasites, resulting in high dose requirements and subsequent intolerable toxicity. Nanosized carriers have been receiving special attention with the aim of minimizing the side effects of drug therapy, such as poor bioavailability and the selectivity of drugs. Several nanosized delivery systems have already proved their effectiveness in animal models for the treatment and prophylaxis of malaria. A number of strategies to deliver antimalarials using nanocarriers and the mechanisms that facilitate their targeting to Plasmodium spp.-infected cells are discussed in this review. Taking into account the peculiarities of malaria parasites, the focus is placed particularly on lipid-based (e.g., liposomes, solid lipid nanoparticles and nano and microemulsions) and polymer-based nanocarriers (nanocapsules and nanospheres). This review emphasizes the main requirements for developing new nanotechnology-based carriers as a promising choice in malaria treatment, especially in the case of severe cerebral malaria.

show abstract

Evaluation of liposomal formulations containing the antimalarial agent, arteether

Cited by 26 publications

References 14 publications

Preparation, characterization, and in vitro evaluation of isoniazid and rifampicin‐loaded archaeosomes

Preparation, characterization, and in vitro evaluation of isoniazid and rifampicin‐loaded archaeosomes

Physicochemical characterisation, drug polymer dissolution and in vitro evaluation of phenacetin and phenylbutazone solid dispersions with polyethylene glycol 8000

Nanotechnology applied to the treatment of malaria

Contact Info

Product

Resources

About